Methods for predicting cardiac toxicity
Methods are disclosed for determining whether organ toxicity, particularly cardiotoxicity, will occur in a patient selected for treatment with various kinase inhibitors, such as tyrosine kinase inhibitors, more particularly erbB inhibitors such as Herceptin. In addition, methods are disclosed for determining whether a potential drug is likely to produce a cardiotoxic effect. The methods involve analyzing lipid levels or the expression fatty acid oxidation enzymes, pAMP activated protein kinase, glucose uptake, to determine whether a fatty acid oxidation disorder is present. The identification of a fatty acid oxidation disorder can be used as a predictor of toxicity, especially cardiac toxicity, and as an indication that organ function should be carefully monitored if a drug such as a tyrosine kinase inhibitor is administered. Methods are also disclosed for protecting organs from metabolic stress and for the treatment of cells, such as adipocytes, to reduce their lipid content.
1. A method for predicting whether a tyrosine kinase inhibitor is toxic to one or more cardiomyocytes, said method comprising:
(a.) treating the one or more cardiomyocytes with the tyrosine kinase inhibitor; and
(b.) measuring a level of lipids in the one or more cardiomyocytes treated with the tyrosine kinase inhibitor,
whereby the tyrosine kinase inhibitor is predicted to be toxic to the one or more cardiomyocytes where the level of lipids in the one or more cardiomyocytes increases upon treatment with the tyrosine kinase inhibitor as compared to cardiomyocytes not treated with the tyrosine kinase inhibitor.
2. The method of claim 1 , wherein the tyrosine kinase inhibitor is a dual tyrosine kinase inhibitor.
3. The method of claim 2 , wherein the tyrosine kinase inhibitor is an erbB inhibitor.
4. The method of claim 2 , wherein the tyrosine kinase inhibitor is an antibody.
5. The method of claim 4 , wherein the antibody is trastuzumab.
6. The method of claim 2 , wherein the tyrosine kinase inhibitor is a small molecule inhibitor.
7. The method of claim 6 , wherein the small molecule inhibitor is GW572016 or GW2974.
8. The method of claim 1 , wherein the lipids are selected from the group consisting of a triglyceride and a cholesterol.
9. A method for predicting cardiac toxicity in response to treatment with a tyrosine kinase inhibitor, said method comprising:
(a.) treating one or more cardiomyocytes with the tyrosine kinase inhibitor; and
(b.) measuring a level of lipids in the one or more cardiomyocytes treated with the tyrosine kinase inhibitor,
whereby a patient is predicted to exhibit cardiac toxicity in response to treatment with the tyrosine kinase inhibitor where the level of lipids in the one or more cardiomyocytes increases upon treatment with the tyrosine kinase inhibitor as compared to cardiomyocytes not treated with the tyrosine kinase inhibitor.
10. The method of claim 9 , wherein the tyrosine kinase inhibitor is a dual tyrosine kinase inhibitor.
11. The method of claim 10 , wherein the tyrosine kinase inhibitor is an erbB inhibitor.
12. The method of claim 10 , wherein the tyrosine kinase inhibitor is an antibody.
13. The method of claim 12 , wherein the antibody is trastuzumab.
14. The method of claim 10 , wherein the tyrosine kinase inhibitor is a small molecule inhibitor.
15. The method of claim 14 , wherein the small molecule inhibitor is GW572016 or GW2974.
16. The method of claim 9 , wherein the lipids are selected from the group consisting of a triglyceride and a cholesterol.
17. The method of claim 1 , wherein the one or more cardiomyocytes are from a population of cardiomyocytes and whereby the tyrosine kinase inhibitor is predicted to be toxic to the population of cardiomyocytes where the level of lipids in the one or more cardiomyocytes increases upon treatment with the tyrosine kinase inhibitor as compared to cardiomyocytes not treated with the tyrosine kinase inhibitor.